株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

びまん性大細胞型B細胞リンパ腫:パイプライン製品の分析

Diffuse Large B-Cell Lymphoma - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 229737
出版日 ページ情報 英文 710 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

2016年12月31日まで 年末キャンペーン割引: Global Markets Direct社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
びまん性大細胞型B細胞リンパ腫:パイプライン製品の分析 Diffuse Large B-Cell Lymphoma - Pipeline Review, H2 2016
出版日: 2016年10月29日 ページ情報: 英文 710 Pages
概要

びまん性大細胞型B細胞リンパ腫は、非ホジキンリンパ腫の一種で、B細胞の癌でもあります。この疾患の場合、リンパ腫は他の人体組織(肝臓・肺・骨など)に転移する可能性があります。主な徴候・症状には、リンパ節肥大化に伴う頚部・腋下・鼠径部の痛みを伴わない腫れや、食欲不振、疲労感、寝汗、原因不明の高熱、体重減少などがあります。現在使用可能な治療法には、放射線治療や化学療法、ステロイド療法と化学療法の組み合わせ、幹細胞サポート・モノクローナル抗体療法を併用した高用量化学療法などがあります。

当レポートでは、世界各国でのびまん性大細胞型B細胞リンパ腫(DLBCL)治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

イントロダクション

びまん性大細胞型B細胞リンパ腫の概要

治療薬の開発

びまん性大細胞型B細胞リンパ腫:企業で開発中の治療薬

びまん性大細胞型B細胞リンパ腫:大学/機関で研究中の治療薬

びまん性大細胞型B細胞リンパ腫:パイプライン製品の概況

びまん性大細胞型B細胞リンパ腫:企業で開発中の製品

びまん性大細胞型B細胞リンパ腫:大学/機関で研究中の製品

びまん性大細胞型B細胞リンパ腫の治療薬開発に従事している企業

びまん性大細胞型B細胞リンパ腫:治療薬の評価

薬剤プロファイル

びまん性大細胞型B細胞リンパ腫:最近のパイプライン動向

びまん性大細胞型B細胞リンパ腫:休止中のプロジェクト

びまん性大細胞型B細胞リンパ腫:休止中のプロジェクト

びまん性大細胞型B細胞リンパ腫:開発が中止された製品

びまん性大細胞型B細胞リンパ腫:製品開発のマイルストーン

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8656IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diffuse Large B-Cell Lymphoma - Pipeline Review, H2 2016, provides an overview of the Diffuse Large B-Cell Lymphoma (Oncology) pipeline landscape.

Diffuse large B-cell lymphoma, a type of non-Hodgkin lymphoma, is a cancer of B-cells. The lymphoma may metastasize to other organs such as the liver, lungs or the bones. The signs and symptoms of diffuse large B-cell lymphoma may include painless swelling in the neck, armpit or groin caused by enlarged lymph nodes, loss of appetite, tiredness, night sweats, unexplained high temperatures, and weight loss. The possible treatments for diffuse large B-cell lymphoma include radiation, chemotherapy, steroid therapy in combination with chemotherapy, high-dose chemotherapy with stem cell support and monoclonal antibody therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diffuse Large B-Cell Lymphoma - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Diffuse Large B-Cell Lymphoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diffuse Large B-Cell Lymphoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Diffuse Large B-Cell Lymphoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 10, 57, 38, 30 and 5 respectively for Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 5, 2, 1 and 1 molecules, respectively for Diffuse Large B-Cell Lymphoma.

Diffuse Large B-Cell Lymphoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Diffuse Large B-Cell Lymphoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Diffuse Large B-Cell Lymphoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Diffuse Large B-Cell Lymphoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Diffuse Large B-Cell Lymphoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Diffuse Large B-Cell Lymphoma (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Diffuse Large B-Cell Lymphoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Diffuse Large B-Cell Lymphoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Diffuse Large B-Cell Lymphoma Overview
  • Therapeutics Development
  • Diffuse Large B-Cell Lymphoma - Therapeutics under Development by Companies
  • Diffuse Large B-Cell Lymphoma - Therapeutics under Investigation by Universities/Institutes
  • Diffuse Large B-Cell Lymphoma - Pipeline Products Glance
  • Diffuse Large B-Cell Lymphoma - Products under Development by Companies
  • Diffuse Large B-Cell Lymphoma - Products under Investigation by Universities/Institutes
  • Diffuse Large B-Cell Lymphoma - Companies Involved in Therapeutics Development
  • Diffuse Large B-Cell Lymphoma - Therapeutics Assessment
  • Drug Profiles
  • Diffuse Large B-Cell Lymphoma - Dormant Projects
  • Diffuse Large B-Cell Lymphoma - Discontinued Products
  • Diffuse Large B-Cell Lymphoma - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Diffuse Large B-Cell Lymphoma, H2 2016
  • Number of Products under Development for Diffuse Large B-Cell Lymphoma - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Development by Companies, H2 2016 (Contd..3)
  • Number of Products under Development by Companies, H2 2016 (Contd..4)
  • Number of Products under Development by Companies, H2 2016 (Contd..5)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Development by Companies, H2 2016 (Contd..4)
  • Products under Development by Companies, H2 2016 (Contd..5)
  • Products under Development by Companies, H2 2016 (Contd..6)
  • Products under Development by Companies, H2 2016 (Contd..7)
  • Products under Development by Companies, H2 2016 (Contd..8)
  • Products under Development by Companies, H2 2016 (Contd..9)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Diffuse Large B-Cell Lymphoma - Pipeline by 3SBio Inc., H2 2016
  • Diffuse Large B-Cell Lymphoma - Pipeline by AbbVie Inc, H2 2016
  • Diffuse Large B-Cell Lymphoma - Pipeline by Acetylon Pharmaceuticals, Inc., H2 2016
  • Diffuse Large B-Cell Lymphoma - Pipeline by Affimed GmbH , H2 2016
  • Diffuse Large B-Cell Lymphoma - Pipeline by Amgen Inc., H2 2016
  • Diffuse Large B-Cell Lymphoma - Pipeline by Arrien Pharmaceuticals, LLC, H2 2016
  • Diffuse Large B-Cell Lymphoma - Pipeline by Arvinas, Inc., H2 2016
  • Diffuse Large B-Cell Lymphoma - Pipeline by Asana BioSciences, LLC, H2 2016
  • Diffuse Large B-Cell Lymphoma - Pipeline by AstraZeneca Plc, H2 2016
  • Diffuse Large B-Cell Lymphoma - Pipeline by Aurigene Discovery Technologies Limited, H2 2016
  • Diffuse Large B-Cell Lymphoma - Pipeline by Bayer AG, H2 2016
  • Diffuse Large B-Cell Lymphoma - Pipeline by BeiGene, Ltd., H2 2016
  • Diffuse Large B-Cell Lymphoma - Pipeline by Biocon Limited, H2 2016
  • Diffuse Large B-Cell Lymphoma - Pipeline by BioNTech AG, H2 2016
  • Diffuse Large B-Cell Lymphoma - Pipeline by Boehringer Ingelheim GmbH, H2 2016
  • Diffuse Large B-Cell Lymphoma - Pipeline by Bristol-Myers Squibb Company, H2 2016
  • Diffuse Large B-Cell Lymphoma - Pipeline by Celgene Corporation, H2 2016
  • Diffuse Large B-Cell Lymphoma - Pipeline by Cell Medica Limited, H2 2016
  • Diffuse Large B-Cell Lymphoma - Pipeline by Cell>Point, L.L.C., H2 2016
  • Diffuse Large B-Cell Lymphoma - Pipeline by Cellular Biomedicine Group, Inc., H2 2016
  • Diffuse Large B-Cell Lymphoma - Pipeline by Clevexel Pharma SA, H2 2016
  • Diffuse Large B-Cell Lymphoma - Pipeline by Constellation Pharmaceuticals, Inc., H2 2016
  • Diffuse Large B-Cell Lymphoma - Pipeline by CSPC Pharmaceutical Group Limited, H2 2016
  • Diffuse Large B-Cell Lymphoma - Pipeline by CTI BioPharma Corp., H2 2016
  • Diffuse Large B-Cell Lymphoma - Pipeline by Curis, Inc., H2 2016
  • Diffuse Large B-Cell Lymphoma - Pipeline by Cyclacel Pharmaceuticals, Inc., H2 2016
  • Diffuse Large B-Cell Lymphoma - Pipeline by eFFECTOR Therapeutics, Inc., H2 2016
  • Diffuse Large B-Cell Lymphoma - Pipeline by Eisai Co., Ltd., H2 2016
  • Diffuse Large B-Cell Lymphoma - Pipeline by EpiZyme, Inc., H2 2016
  • Diffuse Large B-Cell Lymphoma - Pipeline by Erytech Pharma SA, H2 2016
  • Diffuse Large B-Cell Lymphoma - Pipeline by Evotec AG, H2 2016
  • Diffuse Large B-Cell Lymphoma - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
  • Diffuse Large B-Cell Lymphoma - Pipeline by Genentech, Inc., H2 2016
  • Diffuse Large B-Cell Lymphoma - Pipeline by Genosco, H2 2016
  • Diffuse Large B-Cell Lymphoma - Pipeline by Gilead Sciences, Inc., H2 2016
  • Diffuse Large B-Cell Lymphoma - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Diffuse Large B-Cell Lymphoma - Pipeline by H3 Biomedicine Inc., H2 2016
  • Diffuse Large B-Cell Lymphoma - Pipeline by Hutchison MediPharma Limited, H2 2016
  • Diffuse Large B-Cell Lymphoma - Pipeline by ImmunoGen, Inc., H2 2016
  • Diffuse Large B-Cell Lymphoma - Pipeline by Immunomedics, Inc., H2 2016
  • Diffuse Large B-Cell Lymphoma - Pipeline by Immunovaccine, Inc., H2 2016
  • Diffuse Large B-Cell Lymphoma - Pipeline by Incyte Corporation, H2 2016
  • Diffuse Large B-Cell Lymphoma - Pipeline by Inflection Biosciences Limited, H2 2016
  • Diffuse Large B-Cell Lymphoma - Pipeline by Innovent Biologics, Inc., H2 2016
  • Diffuse Large B-Cell Lymphoma - Pipeline by Johnson & Johnson, H2 2016
  • Diffuse Large B-Cell Lymphoma - Pipeline by Juno Therapeutics Inc., H2 2016
  • Diffuse Large B-Cell Lymphoma - Pipeline by Karyopharm Therapeutics, Inc., H2 2016
  • Diffuse Large B-Cell Lymphoma - Pipeline by Kite Pharma Inc, H2 2016
  • Diffuse Large B-Cell Lymphoma - Pipeline by Mabion SA, H2 2016
  • Diffuse Large B-Cell Lymphoma - Pipeline by mAbxience S.A., H2 2016
  • Diffuse Large B-Cell Lymphoma - Pipeline by MedImmune LLC, H2 2016
  • Diffuse Large B-Cell Lymphoma - Pipeline by Medivation, Inc., H2 2016
  • Diffuse Large B-Cell Lymphoma - Pipeline by Merck & Co., Inc., H2 2016
  • Diffuse Large B-Cell Lymphoma - Pipeline by Merck KGaA, H2 2016
  • Diffuse Large B-Cell Lymphoma - Pipeline by Millennium Pharmaceuticals Inc, H2 2016
  • Diffuse Large B-Cell Lymphoma - Pipeline by Mirati Therapeutics Inc., H2 2016
  • Diffuse Large B-Cell Lymphoma - Pipeline by Molplex Ltd., H2 2016
  • Diffuse Large B-Cell Lymphoma - Pipeline by MorphoSys AG, H2 2016
  • Diffuse Large B-Cell Lymphoma - Pipeline by Neumedicines Inc., H2 2016
  • Diffuse Large B-Cell Lymphoma - Pipeline by Nimbus Therapeutics, LLC, H2 2016
  • Diffuse Large B-Cell Lymphoma - Pipeline by Nordic Nanovector ASA, H2 2016
  • Diffuse Large B-Cell Lymphoma - Pipeline by Novartis AG, H2 2016
  • Diffuse Large B-Cell Lymphoma - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016
  • Diffuse Large B-Cell Lymphoma - Pipeline by Pfizer Inc., H2 2016
  • Diffuse Large B-Cell Lymphoma - Pipeline by Philogen S.p.A., H2 2016
  • Diffuse Large B-Cell Lymphoma - Pipeline by Portola Pharmaceuticals, Inc., H2 2016
  • Diffuse Large B-Cell Lymphoma - Pipeline by RedHill Biopharma Ltd., H2 2016
  • Diffuse Large B-Cell Lymphoma - Pipeline by Respiratorius AB, H2 2016
  • Diffuse Large B-Cell Lymphoma - Pipeline by Rhizen Pharmaceuticals S.A., H2 2016
  • Diffuse Large B-Cell Lymphoma - Pipeline by Sandoz International GmbH, H2 2016
  • Diffuse Large B-Cell Lymphoma - Pipeline by Seattle Genetics, Inc., H2 2016
  • Diffuse Large B-Cell Lymphoma - Pipeline by Selvita S.A., H2 2016
  • Diffuse Large B-Cell Lymphoma - Pipeline by Shanghai Henlius Biotech Co., Ltd., H2 2016
  • Diffuse Large B-Cell Lymphoma - Pipeline by Sigma-Tau S.p.A., H2 2016
  • Diffuse Large B-Cell Lymphoma - Pipeline by Taiho Pharmaceutical Co., Ltd., H2 2016
  • Diffuse Large B-Cell Lymphoma - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
  • Diffuse Large B-Cell Lymphoma - Pipeline by TG Therapeutics, Inc., H2 2016
  • Diffuse Large B-Cell Lymphoma - Pipeline by TRACON Pharmaceuticals Inc, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Diffuse Large B-Cell Lymphoma - Dormant Projects, H2 2016
  • Diffuse Large B-Cell Lymphoma - Dormant Projects (Contd..1), H2 2016
  • Diffuse Large B-Cell Lymphoma - Dormant Projects (Contd..2), H2 2016
  • Diffuse Large B-Cell Lymphoma - Dormant Projects (Contd..3), H2 2016
  • Diffuse Large B-Cell Lymphoma - Discontinued Products, H2 2016
  • Diffuse Large B-Cell Lymphoma - Discontinued Products (Contd..1), H2 2016

List of Figures

  • Number of Products under Development for Diffuse Large B-Cell Lymphoma, H2 2016
  • Number of Products under Development for Diffuse Large B-Cell Lymphoma - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top